-
公开(公告)号：US20190313952A1
公开(公告)日：2019-10-17
申请号：US16455468
申请日：2019-06-27
Applicant: DexCom, Inc.
Inventor： Peter C. Simpson , James H. Brauker
IPC: A61B5/145 , A61B5/1486 , C12Q1/00
Abstract: Disclosed herein is an analyte sensing biointerface that comprises a sensing electrode incorporated within a non-conductive matrix comprising a plurality of passageways extending through the matrix to the sensing electrode. Also disclosed herein are methods of manufacturing a sensing biointerface and methods of detecting an analyte within tissue of a host using an analyte sensing biointerface.
-
公开(公告)号：US10376188B2
公开(公告)日：2019-08-13
申请号：US15711225
申请日：2017-09-21
Applicant: DexCom, Inc.
Inventor： Peter C. Simpson , James H. Brauker
Abstract: Disclosed herein is an analyte sensing biointerface that comprises a sensing electrode incorporated within a non-conductive matrix comprising a plurality of passageways extending through the matrix to the sensing electrode. Also disclosed herein are methods of manufacturing a sensing biointerface and methods of detecting an analyte within tissue of a host using an analyte sensing biointerface.
-
公开(公告)号：US20180317827A1
公开(公告)日：2018-11-08
申请号：US16028110
申请日：2018-07-05
Applicant: DexCom, Inc.
Inventor： James H. Brauker , Mark C. Shults , Mark A. Tapsak
IPC: A61B5/1473 , A61B5/07 , A61B5/1486 , A61L31/14 , A61B5/145 , A61L31/10
CPC classification number: A61B5/14735 , A61B5/076 , A61B5/14532 , A61B5/14546 , A61B5/14865 , A61B2562/02 , A61L31/10 , A61L31/14 , Y10T428/249921
Abstract: The present invention provides a biointerface membrane for use with an implantable device that interferes with the formation of a barrier cell layer including; a first domain distal to the implantable device wherein the first domain supports tissue attachment and interferes with barrier cell layer formation and a second domain proximal to the implantable device wherein the second domain is resistant to cellular attachment and is impermeable to cells. In addition, the present invention provides sensors including the biointerface membrane, implantable devices including these sensors or biointerface membranes, and methods of monitoring glucose levels in a host utilizing the analyte detection implantable device of the invention. Other implantable devices which include the biointerface membrane of the present invention, such as devices for cell transplantation, drug delivery devices, and electrical signal delivery or measuring devices are also provided.
-
公开(公告)号：US20180185587A1
公开(公告)日：2018-07-05
申请号：US15906946
申请日：2018-02-27
Applicant: DexCom, Inc.
Inventor： James H. Brauker , Mark A. Tapsak , Sean T. Saint , Apurv Ullas Kamath , Paul V. Neale , Peter C. Simpson , Michael Robert Mensinger , Dubravka Markovic
CPC classification number: A61M5/31525 , A61B5/0002 , A61B5/14532 , A61B5/1486 , A61B5/14865 , A61B5/4839 , A61B2560/0443 , A61M5/1723 , A61M11/00 , A61M15/0001 , A61M2005/1726 , A61M2205/18 , A61M2205/3303 , A61M2205/502 , A61M2205/52 , A61M2230/201 , G06F19/3468 , G16H20/17 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
-
公开(公告)号：US20180043096A1
公开(公告)日：2018-02-15
申请号：US15792038
申请日：2017-10-24
Applicant: DexCom, Inc.
Inventor： John Michael Dobbles , Apurv Ullas Kamath , Aarthi Mahalingam , James H. Brauker
IPC: A61M5/172 , A61M15/00 , A61B5/145 , A61M5/142 , A61M11/00 , A61M35/00 , G06F19/00 , A61M5/20 , A61B5/00 , A61M5/178 , A61M5/00 , A61M5/30
CPC classification number: A61M5/1723 , A61B5/0031 , A61B5/14532 , A61B5/14546 , A61M5/003 , A61M5/14244 , A61M5/14276 , A61M5/178 , A61M5/20 , A61M5/30 , A61M11/00 , A61M15/00 , A61M15/0065 , A61M15/0068 , A61M15/008 , A61M15/0083 , A61M35/00 , A61M2005/14296 , A61M2205/3569 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/582 , A61M2205/587 , A61M2205/8206 , A61M2230/201 , G06F19/3468 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
-
Patent Agency Ranking
公开(公告)号：US09801572B2
公开(公告)日：2017-10-31
申请号：US14743777
申请日：2015-06-18
Applicant: DexCom, Inc.
Inventor： Mark C. Brister , Paul V. Neale , James H. Brauker
IPC: A61B5/1473 , A61B5/1486 , A61B5/1495 , A61B5/05 , A61M5/14 , A61B5/145 , A61B5/00 , A61B5/15 , A61B17/34 , A61M5/172 , A61M5/158 , A61M5/142
CPC classification number: A61B5/14532 , A61B5/0002 , A61B5/0004 , A61B5/05 , A61B5/14 , A61B5/1411 , A61B5/145 , A61B5/14503 , A61B5/14507 , A61B5/14514 , A61B5/14546 , A61B5/1468 , A61B5/1473 , A61B5/14735 , A61B5/1486 , A61B5/14865 , A61B5/1495 , A61B5/150022 , A61B5/6801 , A61B5/6832 , A61B5/6833 , A61B5/6848 , A61B5/6849 , A61B5/72 , A61B17/3468 , A61B2017/3492 , A61B2560/0223 , A61B2560/045 , A61M5/14 , A61M5/14244 , A61M5/1723 , A61M2005/1585 , G06F19/00 , Y02A90/26
Abstract: The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.
-
公开(公告)号：US20170245802A1
公开(公告)日：2017-08-31
申请号：US15595828
申请日：2017-05-15
Applicant: DexCom, Inc.
Inventor： Paul V. Goode , James H. Brauker , Arpurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
IPC: A61B5/00 , A61B5/1473 , A61B5/1486 , A61B5/145
CPC classification number: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
-
公开(公告)号：US09572935B2
公开(公告)日：2017-02-21
申请号：US14063753
申请日：2013-10-25
Applicant: DexCom, Inc.
Inventor： John Michael Dobbles , Apurv Ullas Kamath , Aarthi Mahalingam , James H. Brauker
IPC: A61M5/172 , A61B5/145 , A61M5/142 , G06F19/00 , A61B5/00 , A61M5/00 , A61M5/178 , A61M5/30 , A61M11/00 , A61M15/00
CPC classification number: A61M5/1723 , A61B5/0031 , A61B5/14532 , A61B5/14546 , A61M5/003 , A61M5/14244 , A61M5/14276 , A61M5/178 , A61M5/20 , A61M5/30 , A61M11/00 , A61M15/00 , A61M15/0065 , A61M15/0068 , A61M15/008 , A61M15/0083 , A61M35/00 , A61M2005/14296 , A61M2205/3569 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2205/581 , A61M2205/582 , A61M2205/587 , A61M2205/8206 , A61M2230/201 , G06F19/00 , G06F19/3468 , G16H40/63
Abstract: Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Abstract translation: 提供了用于集成包括接收器14，药物输送装置16，控制器模块和任选的单点葡萄糖监测器18的连续葡萄糖传感器12的系统和方法。 集成可以是手动，半自动化和/或完全自动化。
-
公开(公告)号：US09532741B2
公开(公告)日：2017-01-03
申请号：US14341468
申请日：2014-07-25
Applicant: DexCom, Inc.
Inventor： James H. Brauker , Mark C. Shults , Mark A. Tapsak
IPC: A61B5/145 , A61B5/1473 , A61B5/07 , A61B5/1486 , A61L31/10 , A61L31/14
CPC classification number: A61B5/14735 , A61B5/076 , A61B5/14532 , A61B5/14546 , A61B5/14865 , A61B2562/02 , A61L31/10 , A61L31/14 , Y10T428/249921
Abstract: The present invention provides a biointerface membrane for use with an implantable device that interferes with the formation of a barrier cell layer including; a first domain distal to the implantable device wherein the first domain supports tissue attachment and interferes with barrier cell layer formation and a second domain proximal to the implantable device wherein the second domain is resistant to cellular attachment and is impermeable to cells. In addition, the present invention provides sensors including the biointerface membrane, implantable devices including these sensors or biointerface membranes, and methods of monitoring glucose levels in a host utilizing the analyte detection implantable device of the invention. Other implantable devices which include the biointerface membrane of the present invention, such as devices for cell transplantation, drug delivery devices, and electrical signal delivery or measuring devices are also provided.
Abstract translation: 本发明提供了一种用于与可植入装置一起使用的生物界面膜，其干扰屏障细胞层的形成，包括： 远离植入装置的第一区域，其中第一结构域支持组织附着并干扰阻挡细胞层形成，以及邻近可植入装置的第二结构域，其中第二结构域对细胞附着有抗性并且对细胞是不可渗透的。 此外，本发明提供了包括生物界面膜，包括这些传感器或生物界面膜的可植入装置的传感器，以及利用本发明的分析物检测可植入装置监测宿主中的葡萄糖水平的方法。 还提供了包括本发明的生物界面膜的其它可植入装置，例如用于细胞移植的装置，药物递送装置和电信号传递或测量装置。
-
170.发明申请SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM 有权用于在葡萄糖传感器数据流中替换信号文件的系统和方法公开(公告)号：US20160302731A1
公开(公告)日：2016-10-20
申请号：US15197349
申请日：2016-06-29
Applicant: DexCom, Inc.
Inventor： Paul V. Goode , James H. Brauker , Arpurv U. Kamath , James Patrick Thrower , Victoria Carr-Brendel
IPC: A61B5/00 , A61B5/1473 , A61B5/145
CPC classification number: A61B5/7203 , A61B5/0004 , A61B5/0031 , A61B5/14532 , A61B5/14539 , A61B5/14542 , A61B5/1473 , A61B5/14865 , A61B5/1495 , A61B5/7225 , A61B5/7257 , A61B5/726 , A61B5/7278 , A61B5/742 , A61B5/7475 , A61B2560/0223 , A61B2562/0247 , A61B2562/0271 , A61B2562/08
Abstract: Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.
Abstract translation: 用于最小化或消除由于非葡萄糖速率限制现象（如缺血，pH变化，温度变化等）引起的瞬时非葡萄糖相关信号噪声的系统和方法。 系统监测来自葡萄糖传感器的数据流，并检测具有比电子或扩散相关系统噪声更高的幅度的信号伪像。 该系统连续地或间歇地替代一些或整个数据流，包括特别地解决瞬态信号伪影的信号估计方法。 该系统还能够检测信号伪像的严重性并且响应于信号伪像的严重性选择性地应用一个或多个信号估计算法因子，其包括选择性地将不同的参数集合应用于信号估计算法或选择性地应用不同信号 估计算法。
-
-
-
-
-
-
-
-
-
Search Results
222
records
(took 0.046 seconds)
